The Global LiverFibrosis Treatment Market, segmented by Treatment Type (PeroxisomeProliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors,Hepatotropic Drug, and Others), by Condition (Chronic Liver Diseases, HepatitisC, and Nonalcoholic Steatohepatitis), by End User (Hospitals, SpecialtyClinics, and Others), and by Region (North America, Latin America, Europe, AsiaPacific, the Middle East, and Africa) is projected to exhibit a CAGR of 10.8%over the forecast period (2018 - 2026).
Increasing number of clinicaltrials by key players focused on development of an efficient treatment optionfor liver fibrosis is expected to drive the growth of the liver fibrosistreatment market in near future. In October 2010, FibroGen, Inc. initiatedphase II clinical study of FG-3019: a human monoclonal antibody against theConnective Tissue Growth Factor (CTGF) to compare the efficacy in reversing theeffects of liver fibrosis caused by chronic infection with hepatitis B virus(HBV). In February 2018, Intercept Pharmaceuticals, Inc. initiated phase IIItrial of REVERSE trial (Randomized Phase 3 Study Evaluating the Efficacy andSafety of Obeticholic Acid in Subjects with Compensated Cirrhosis Due toNonalcoholic Steatohepatitis). This randomized phase III study will evaluatethe efficacy and safety of obeticholic acid in NASH patients with abiopsy-confirmed diagnosis of cirrhosis.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2320
Browse 24 Market Data Tables and28 Figures spread through 168 Pages and in-depth TOC on ‘Liver FibrosisTreatment Market, by Treatment Type (Peroxisome Proliferator-activatedReceptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, and Others),by Condition (Chronic Liver Diseases, Hepatitis C, and NonalcoholicSteatohepatitis), by End User (Hospitals, Specialty Clinics, and Others), andby Region (North America, Latin America, Europe, Asia Pacific, the Middle East,and Africa) - Global Forecast to 2026’
Furthermore, growing research collaborationamong the key players to develop novel treatment regime combined withregulatory approval of underline drugs for treatment of liver fibrosis isexpected to drive the market growth in near future. For instance, in April2017, Bristol-Myers Squibb Company and Nordic Bioscience signed a collaborationagreement for development of biomarker technology to potentially diagnose andmonitor fibrosis disease including Non-alcoholic steatohepatitis (NASH). Thiscollaboration will help patients to efficiently diagnose and monitor fibrosisdisease. In February 2018, the U.S. Foodand Drug Administration (FDA) approved Vertex Pharmaceuticals’ SYMDEKO(tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF)in people age 12 and older with certain mutations.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/liver-fibrosis-treatment-market-2320
Key Takeaways of the LiverFibrosis Treatment Market:
The global liver fibrosistreatment market is expected to grow at 10.8% CAGR over the forecast period,owing to increasing prevalence of risk factors affecting liver fibrosis,worldwide.
Among treatment type, hepatotropicdrug accounted for significant market share in liver fibrosis treatment market,as it enables safe and efficient treatment for reducing fibrosis in patients.
Among end users, hospitalssegment is expected to account for major market share during the forecastperiod, as hospital offer primary treatment option for patient suffering withliver fibrosis.
Some of the major playersoperating in the global liver fibrosis treatment market include GileadSciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson andJohnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc.,FibroGen, Inc., and Pharmaxis Limited.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2320
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
